Cyclic peptide and imaging compound compositions and uses...

Details Cyclic peptide and imaging compound compositions and uses... Cyclic peptide and imaging compound compositions and uses...

2008-05-13

2008-05-13

Tsang, Cecilia J (Department: 1654)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C514S009100, C530S317000

Reexamination Certificate

active

07371364

ABSTRACT:
The present invention relates to novel cyclic peptides that may be conjugated with imaging agents, including novel imaging agents. Specifically, it includes c(KRGDf; SEQ ID NO. 3) NIR imaging compositions and novel cyclic HWGFTL (SEQ ID NO. 5) polypeptides which may be used inter alia in NIR, MRI and nuclear imaging as well as therapy. Additionally, the invention includes novel imaging agents, such as TS-ICG derivatives. The invention also relates to methods of making and using such compounds. Such uses include both pre-operative and intraoperative detection of tumor cells and treatment monitoring.

REFERENCES:
patent: 93/12819 (1993-07-01), None
patent: 9312819 (1993-07-01), None
patent: 97/47750 (1999-09-01), None
patent: 9947550 (1999-09-01), None
patent: 02/076451 (2002-10-01), None
patent: 02076451 (2002-10-01), None
International Search Report PCT/US2004/026220.
Erkki Koivunen et al., “Tumor targeting with a selective gelatinase inhibitor,” Nature Biotechnology, vol. 17, pp. 768-774, Aug. 1999.
Peter C. Brooks et al., “Requirement of Vascular Integrin ανβ3for Angiogensis,” Science, vol. 264, pp. 569-571, Apr 22, 1994.
Martin Friedlander et al., “Definition of Two Angiogenic Pathways by Distinct ανIntegrins,” Science, vol. 270, pp. 1500-1502, Dec. 1, 1995.
Renata Pasqualini et al., “αν Integrins as receptors for tumor targeting by circulating ligands,” Nature Biotechnology, vol. 15, pp. 542-546, Jun. 1997.
Dorothy A. Sipkins et al., “Detection of tumor angiogenesis in vivo by ανβ3-targeted magnetic resonance imaging,” Nature Medicine, vol. 4, No. 5, pp. 623-626, May 1998.
Giampietro Gasparini et al., “Vascular Integrin: A New Prognostic Indicator in Breast Cancer,” Clinical Cancer Research, vol. 4, pp. 2625-2634, Nov. 1998.
Brian P. Eliceiri et al., “The role of αν integrins during angiogenesis: insights into potential mechanisms of action and clinical development,” The Journal of Clinical Investigation , vol. 103, No. 9, pp. 1227-1230, May 1999.
Roland Haubner et al., “Radiolabeled ανβ3Integrin Antagonists: A New Class of Tracers for Tumor Targeting,” The Journal of Nuclear Medicine, vol. 40, No. 6, pp. 1061-1071, Jun. 1999.
John C. Gutheil et al., “Targeted Antiangiogenic Therapy for Cancer Using Vitaxin: A Humanized Monoclonal Antibody to the Integrin ανβ3,” Clinical Cancer Research, vol. 6, pp. 3056-3061, Aug. 2000.
C. Chandra Kumar et al., “Inhibition of Angiogenesis and Tumor Growth by SCH221153, a Dual ανβ3 and ανβ5 Integrin Receptor Antagonist,” Cancer Research, vol. 61, pp. 2232-2238, Mar. 1, 2001.
Roland Haubner et al., “Noninvasive Imaging of ανβ3 Integrin Expression Using F-labeled RGD-containing Glycopeptide and Positron Emission Topography,:” Cancer Research, pp. 1781-1785, Mar. 1, 2001.
Oula Penate Medina et al., “Binding of Novel Peptide Inhibitors of Type IV Collagenases to Phospholipid Membranes and Use in Liposome Targeting to Tumor Cells in Vitro,” Cancer Research, pp. 3978-3985, May 15, 2001.
Niels Reinmuth et al., “ανβ3 Integrin Antagonist S247 Decreases Colon Cancer Metastasis and Angiogenesis and Improves Survival in Mice,”Cancer Research, vol. 63, pp. 2079-2087, May 1, 2003.
Invitation to pay additional fees for PCT/US2004/026220, Jan. 10, 2005.
International Search Report and Written Opinion PCT/US2004/026220, 17 pages.
Transmittal of Copy of International Preliminary Report on Patentability; PCT/US2004/026220; pp. 10, Mailing Date Mar. 2, 2005.
E. Koivunen et al.; “Tumor Targeting with a Selective Gelatinase Inhibitor”; Nat/ure Biotechnology, vol. 17; pp. 768-774, Aug. 1999.
Oula Penate Medina et al.; “Binding of Novel Peptide Inhibitor of Type IV Collagenases to Phospholipid Membranes and use in Liposome Targeting to Tumor Cells in Vitro”; Cancer Research, American Association For Cancer Research, vol. 61; pp. 3978-3985, May, 15, 2001.

Affiliated with

Also associated with

Rating

Cyclic peptide and imaging compound compositions and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclic peptide and imaging compound compositions and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic peptide and imaging compound compositions and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2770073